Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
about
Binimetinib for the treatment of NRAS-mutant melanoma.Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.Correlation between STK33 and the pathology and prognosis of lung cancer.After a treatment breakthrough-progress, plateaus, and raising the bar.HAX-1 Protects Glioblastoma Cells from Apoptosis through the Akt1 Pathway.Hematopoietic Substrate-1-Associated Protein X-1 Regulates the Proliferation and Apoptosis of Endothelial Progenitor Cells Through Akt Pathway Modulation.Why target the tumor stroma in melanoma?Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.The Adhesion G-Protein-Coupled Receptor, GPR56/ADGRG1, Inhibits Cell-Extracellular Matrix Signaling to Prevent Metastatic Melanoma Growth.Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With Mutation Detected in Circulating-Free DNACombatting mucosal melanoma: recent advances and future perspectives
P2860
Q38636033-4AAFE85B-F593-40BC-9D1B-140C6A2D4823Q39434922-4B2D7162-E495-421D-858A-0E35AF6F45B5Q45706786-2607D923-D996-415D-8055-78B55D51F70CQ46492858-29FF1345-975D-405B-9F60-3571EE11394AQ47222181-A58C0FA7-E58A-44CB-93B9-BBFA0852B61EQ47400845-611ADA4D-31AD-407B-85E0-CD21F3E2930CQ47645232-4DC26EEB-B74A-42F0-BEDF-6DAEFBF494CFQ48251370-E7B23FDE-2325-4615-A1CB-1FAE83E6A402Q49449261-D8AC9D9D-5703-4D61-92A2-582977BC93D4Q49787884-05FB3CBE-47BB-4B67-9D29-95865C6DEF9CQ50086506-C9D7182E-4EF4-46CB-9271-32A3B1A730C4Q58781162-484BB8D7-5162-401B-98D0-FB9D542087F9Q59126427-F4882552-4787-4B5A-ACC5-63BC9BF04E53
P2860
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Mechanisms and strategies to o ...... targeted therapy for melanoma.
@en
Mechanisms and strategies to o ...... targeted therapy for melanoma.
@nl
type
label
Mechanisms and strategies to o ...... targeted therapy for melanoma.
@en
Mechanisms and strategies to o ...... targeted therapy for melanoma.
@nl
prefLabel
Mechanisms and strategies to o ...... targeted therapy for melanoma.
@en
Mechanisms and strategies to o ...... targeted therapy for melanoma.
@nl
P2860
P50
P356
P1433
P1476
Mechanisms and strategies to o ...... targeted therapy for melanoma.
@en
P2860
P304
P356
10.1002/CNCR.30435
P407
P577
2017-06-01T00:00:00Z